Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT05554419
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT05554393
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 335
- Registration Number
- NCT05554406
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
🇺🇸Essentia Health Cancer Center, Duluth, Minnesota, United States
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-03-19
- Target Recruit Count
- 68
- Registration Number
- NCT05536154
- Locations
- 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳Jinhua People's Hospital, Jinhua, Zhejiang, China
🇨🇳Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05521087
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-10-10
- Target Recruit Count
- 62
- Registration Number
- NCT05510089
- Locations
- 🇨🇳
Huzhou central hospital, Huzhou, Zhejiang, China
🇨🇳Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳The Affiliated People's Hospital of Ningbo University., Ningbo, Zhejiang, China
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT05476770
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
ChiCGB vs BEAM in High-risk or R/R Lymphomas
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 306
- Registration Number
- NCT05466318
- Locations
- 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳West China Hospital, Sichuan University, Chendu, Sichuan, China
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05453903
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Novant Health, Charlotte, North Carolina, United States
🇺🇸Albert Einstein College Of Medicine, New York, New York, United States
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT05404516
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.